Image of An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer

LITERATURE

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer


Androgen deprivation therapy (ADT) is the mainstay palliative treatment for men with locally advanced and metastatic prostate
cancer, and aims to reduce testosterone to levels obtained by surgical castration. Use of gonadotropin-releasing hormone (GnRH)
agonists predominates among the ADT options. The GnRH agonist, triptorelin is a first-line hormonal therapy that has demonstrated efficacy and safety in clinical trials of patients with locally advanced non-metastatic or metastatic disease. Sustained-release 1-, 3- and 6-month formulations of triptorelin, administered intramuscularly or subcutaneously, have been developed to provide improved flexibility and convenience for the patient.


Availability

Pamorelin-005Available

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
Adv Ther (2016) 33:1072–1093
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous